Introduction
In 1966 we published recommendations for the prevention of tetanus in the wounded,' which took into account the fundamental importance of active immunization and the need, in non-immune wounded patients, to limit the use of equine antitoxin and to place greater reliance on the use of antimicrobials to supplement careful surgical toilet. The use of human tetanus immunoglobulin was also recommended, as preferable to either equine antitoxin or antimicrobials, but in 1966 the material was scarce. Toxoid complete course + human tetanus mmunoglobulin Has had a complete course of toxoid or a booster dose within the past 5 years Has had a complete course of toxoid ora booster dose more than 5 and less than 10 years ago Has had a complete course of toxoid ora booster dose more than 10 years ago
Has not had a complete course of toxoid or immunity status is unknown anaphylactic shock, have been described."' 12 These usually occur in patients given repeated injections for treatment of hypogammaglobulinaemia, but severe reactions are extremely unlikely to occur in healthy patients who receive human immunoglobulin only for tetanus prevention. A trial dose of immunoglobulin to predict the occurrence of anaphylactic shock is therefore unnecessary, just as it is in the case of vaccines used for routine immunization. Nevertheless, as with any immunization procedure, adrenaline should be immediately available whenever immunoglobulin is given.
Toxoid ACTIVE IMMUNIZATION
For active immunization adsorbed toxoid is recommended-that is, toxoid containing an aluminium adjuvant (adsorbed tetanus toxoid B.P.). Adsorbed toxoid is effective when given at the same time as antitoxin (but into a different limb), stimulates a higher, longer-lasting antitoxin response than plain toxoid, and is satisfactory for boosting immunity in wounded people.'3 Plain toxoid is therefore not recommended.
A complete basic course comprises three spaced doses of toxoid, with, for example, about six weeks between the first and second doses and six to 12 months between the second and third; longer intervals between doses are acceptable, but are less convenient administratively. Routine booster doses are recommended at 10-year intervals unless during this period the patient has received a booster dose at the time of wounding.
The period for which antitoxin is found in the blood of actively immunized people after a complete basic course of adsorbed tetanus toxoid is uncertain, but evidence is accumulating that immunity usually lasts for 10 years, though it is less durable after plain toxoid. 5-7
After a booster dose of adsorbed toxoid immunity is believed to last even longer, but until it is established that this is almost invariably the case booster doses are recommended at 10-year intervals.
ROLE OF THE BOOSTER DOSE AT INJURY
The recommendation that a booster dose is given at injury to those immunized or boosted between five and 10 years previously is made for three reasons. Firstly, it is desirable to stimulate an increase in the blood antitoxin when the patient may be faced with the challenge of toxin production in a wound. Secondly, there is the possibility that some people may have responded inadequately to the tetanus toxoid given earlier,5 7 13 l and may thus lack circulating antitoxin at the time of injury. This is most likely in those who were immunized with plain toxoid,5 "I and since adsorbed toxoid was introduced in the United Kindgom only in 1963, there will still be many such people. Thirdly, it is desirable to take the opportunity of boosting the patient's immunity to ensure that he will remain actively immune for many years.
Recommendations for prevention of tetanus in the wounded. Adrenaline injection (B.P.) should be available during prophylactic procedures for treatment of anaphylactic shock (in adults 0-5-1 ml intramuscularly).
The booster dose of toxoid for wounded patients immunized more than 10 years earlier is recommended for similar reasons but, owing to the longer time interval, there is a greater possibility that circulating antitoxin may be absent in such patients, particularly since most of them will have been immunized with plain toxoid. Moreover, their booster response may be slow"-that is, tetanus toxin might be produced in a wound before antitoxin appears in the circulation; for this reason human tetanus immunoglobulin is recommended.
HYPERSENSITIVITY OF TETANUS TOXOID
Hypersensitivity reactions-usually pain at the site of injection-may occur, particularly when tetanus toxoid is given frequently to boost immunity, as for example in factory workers receiving minor wounds.3 4 Unnecessary booster doses of toxoid should therefore be avoided.
Immunity Categories
The measures to be recommended for tetanus prevention in a wounded patient depend on whether or not he has been actively immunized and on the degree of immunity he is likely to possess. It is therefore necessary to evaluate the immunity of each patient and we suggest that the following four categories be used.
Immunity Category A.-The patient has had a complete basic course of toxoid or a booster within the past five years. He 
